Jun 02, 2021 / 05:30AM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Conference Call regarding the clinical development of PRX-102 for the treatment of Fabry disease. As a reminder, this conference call is being recorded.
I will now turn the conference over to our host, Mr. Chuck Padala of LifeSci Advisors, Investor Relations. You may begin your conference.
Charles Padala -
All right. Thank you, Rob. Welcome to the Protalix Conference Call regarding the clinical development of PRX-102 for the treatment of Fabry disease. With me today are Dror Bashan, President and CEO of Protalix; and Eyal Rubin, Chief Financial Officer. Mr. Bashan and Mr. Rubin are joined today by Mr. Ulrich Granzer, PhD, of Granzer Regulatory Consulting & Services. The agency provides Protalix and Chiesi with consulting services related to drug development and regulatory affairs.
Dr. Granzer is a founding member of the German Association of Regulatory Affairs, where he is the current President of the Board and Co-Founder of the European Union Regulatory Affairs Group
Protalix Biotherapeutics Inc Updates On PRX-102 - Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot